Business description: MannKind Corporation

MannKind Corporation is a biopharmaceutical company. It is focused on the development and commercialization of inhaled therapeutic products for patients with endocrine and orphan lung diseases. Its technologies include Technosphere dry-powder formulations and Dreamboat inhalation devices, which offers delivery of medicines to the deep lung where they can exert an effect locally or enter the systemic circulation. Its products include Afrezza (insulin human) Inhalation Powder and the V-Go wearable insulin delivery device. The Afrezza (insulin human) Inhalation Powder is an inhaled insulin indicated to enhance glycemic control in adults with diabetes. The V-Go wearable insulin delivery device provides subcutaneous infusion of insulin in adults that require insulin. Its orphan lung disease pipeline includes Tyvaso DPI (treprostinil) inhalation powder for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD).

Number of employees: 592

Sales by Activity: MannKind Corporation

Fiscal Period: December 2021 (USD) 2022 (USD) 2023 (USD) 2024 (USD) 2025 (USD)

Pharmaceuticals

75.44M 99.77M 199M 286M 349M

Geographical breakdown of sales: MannKind Corporation

Fiscal Period: December 2021 (USD) 2022 (USD) 2023 (USD) 2024 (USD) 2025 (USD)

United States of America

75.44M 99.77M 199M 286M 349M

Executive Committee: MannKind Corporation

Manager TitleAgeSince
Chief Executive Officer 49 24/05/2017
Director of Finance/CFO 51 21/04/2024
Chief Tech/Sci/R&D Officer - 28/09/2025
Chief Tech/Sci/R&D Officer 59 30/09/2022
Chief Tech/Sci/R&D Officer - 30/08/2020

Composition of the Board of Directors: MannKind Corporation

Director TitleAgeSince
Director/Board Member 82 30/09/2003
Director/Board Member 82 30/11/2003
Chairman 69 08/12/2020
Director/Board Member 49 24/05/2017
Director/Board Member 63 12/08/2024
Director/Board Member 57 26/11/2018
Director/Board Member 71 31/12/2019
Director/Board Member 54 22/03/2020
Director/Board Member 63 30/11/2020

Shareholders: MannKind Corporation

NameEquities%Valuation
BlackRock Advisors LLC
8.751 %
26,872,119 8.751 % 88 M $
Vanguard Fiduciary Trust Co.
5.823 %
17,880,873 5.823 % 59 M $
4.762 %
14,623,269 4.762 % 48 M $
Rubric Capital Management LP
2.435 %
7,476,495 2.435 % 25 M $
Geode Capital Management LLC
2.401 %
7,374,138 2.401 % 24 M $

Company details: MannKind Corporation

MannKind Corp.

1 Casper Street

06810, Danbury

+818 661 5000

http://www.mannkindcorp.com
address MannKind Corporation(MNKD)

Bio Therapeutic Drugs

Change 5d. change 1-year change 3-years change Capi.($)
-2.61%-10.77%-47.70%-41.61% 804M
+0.34%-0.12%+22.68%+96.75% 45.56B
+3.35%+0.43%+51.85%+17.36% 40.81B
+0.50%-2.14%+96.87%+700.06% 31.01B
-17.88%-16.74%-20.37%-34.18% 21.05B
-1.42%+2.27%+49.79%-28.09% 19.37B
-1.55%-1.51%+27.82%-29.14% 17.15B
-0.09%+20.57%+62.75%+189.79% 13.54B
+3.88%+8.07%-9.23%+995.97% 12.66B
-1.79%+16.72%+65.93% - 12.33B
Average -1.70%+1.34%+30.04%+207.43% 21.43B
Weighted average by Cap. -1.09%+0.76%+40.47%+199.10%
  1. Stock Market
  2. Equities
  3. MNKD Stock
  4. Company MannKind Corporation
SPRING SALE -40%: The Best Tools Reserved for Subscribers to Identify Tomorrow's Top Investments!
d
:
:
BENEFIT NOW